Aptorum Group and DiamiR Receive New York State Approval for APOE Genotyping Test
ByAinvest
Saturday, Aug 23, 2025 12:57 am ET1min read
APM--
DiamiR Biosciences and Aptorum Group announced that DiamiR received approval from the New York State Department of Health for its APOE Genotyping test. The test is now available for use in a variety of biological samples through DiamiR's Clinical Laboratory Improvement Amendments certified, College of American Pathologists accredited clinical laboratory. This approval allows DiamiR to offer the test nationwide.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet